**FROM THE EDITOR**

499 In This Issue
Scott M. Lippman

**PERSPECTIVES**

500 Metformin and Hepatic Carcinogenesis
Michael Pollak and Ana M. Gonzalez-Angulo
*Perspective on Bhalla et al., p. 544*

503 Prevention of Mutagenesis: New Potential Mechanisms of Metformin Action in Neoplastic Cells
Frédéric Bost, Issam Ben-Sahra, and Jean-François Tanti
*Perspective on Algire et al., p. 536*

507 Diagnosing Lynch Syndrome: More Light at the End of the Tunnel
Randall W. Burt
*Perspective on Yurgelun et al., p. 574*

511 Simplifying the Energy Balance Message for Breast Cancer Prevention
Carol J. Fabian
*Perspective on Cecchini et al., p. 583*

**MINIREVIEWS**

515 Obesity and the Risk for Premenopausal and Postmenopausal Breast Cancer
Garnet L. Anderson and Marian L. Neuhouser

522 Genetic Predisposition to Chronic Obstructive Pulmonary Disease and/or Lung Cancer: Important Considerations When Evaluating Risk
Randa A. El-Zein Robert P. Young, Raewyn J. Hopkins, and Carol J. Etzel

**COMMENTARY**

528 The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: A Unique Resource for Defining the “Molecular Histology” of the Breast
Mark E. Sherman, Jonine D. Figueroa, Jill E. Henry, Susan E. Clare, Connie Rufenbarger, and Anna Maria Storniolo

**RESEARCH ARTICLES**

536 Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage
Carolyn Algire, Olga Moiseeva, Xavier Deschénes-Simard, Lilian Amrein, Luca Petrusselli, Elena Birman, Benoit Viollet, Gerardo Ferbeyre, and Michael N. Pollak
*See perspective on p. 503*

544 Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis
*See perspective on p. 500*

553 Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin Signaling
Nanthakumar Subramaniam, Mara H. Sherman, Renuka Rao, Caroline Wilson, Sally Coulter, Annette R. Atkins, Ronald M. Evans, Christopher Liddle, and Michael Downes

562 Metformin Prevents the Development of Oral Squamous Cell Carcinomas from Carcinogen-Induced Premalignant Lesions
Lynn Vitale-Cross, Alfredo A. Molinolo, Daniel Martin, Rania H. Younis, Takashi Maruyama, Vyomesh Patel, Wanjun Chen, Abraham Schneider, and J. Silvio Gutkind

574 Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps
Matthew B. Yurgelun, Ajay Goel, Jason L. Hornick, Ananda Sen, Danielle Kim Turgeon, Mack T. Ruffin IV, Norman E. Marcon, John A. Baron, Robert S. Bresalier, Sapna Syngal, Dean E. Brenner, C. Richard Boland, and Elena M. Stoffel
*See perspective on p. 507*
Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials

Reena S. Cecchini, Joseph P. Costantino, Jane A. Cauley, Walter M. Cronin, D. Lawrence Wickerham, Stephanie R. Land, Joel L. Weissfeld, and Norman Wolmark

See perspective on p. 511

Carnosol, a Constituent of Zyflamend, Inhibits Aryl Hydrocarbon Receptor–Mediated Activation of CYP1A1 and CYP1B1 Transcription and Mutagenesis

Arash Mohebati, Joseph B. Guttenplan, Amit Kochhar, Zhong-Lin Zhao, Wieslawa Kosinska, Kotha Subbaramaiah, and Andrew J. Dannenberg

Protection of Humans by Plant Glucosinolates: Efficiency of Conversion of Glucosinolates to Isothiocyanates by the Gastrointestinal Microflora

Jed W. Fahey, Scott L. Wehage, W. David Holtzclaw, Thomas W. Konsler, Patricia A. Egner, Theresa A. Shapiro, and Paul Talalay

The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition

Bo Li, Hui Ren, Ping Yue, Mingwei Chen, Fadlo R. Khuri, and Shi-Yong Sun

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

Edward Messing, Jason R. Gee, Daniel R. Saltzstein, KyungMan Kim, Anthony diSant’Agnese, Jill Kolesar, Linda Harris, Adrienne Faerber, Thomas Havighurst, Jay M. Young, Mitchell Efros, Robert H. Getzenberg, Marcia A. Wheeler, Joseph Tangrea, Howard Barnes, Margaret House, J. Erik Busby, Raymond Hohl, and Howard Bailey

Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade In Vitro and In Vivo

Peramaityan Rajendran, Feng Li, Muthu K. Shanmugam, Radhamani Kannaiyan, Jen Nee Goh, Kwong Fai Wong, Wei Wang, Elster Khin, Vinay Tergaonkar, Alan Prem Kumar, John M. Luk, and Gautam Sethi

LETTERS TO THE EDITOR

Lung Cancer Risk Prediction to Select Smokers for Screening CT—Letter

Robert P. Young and Raewyn J. Hopkins

Lung Cancer Risk Prediction to Select Smokers for Screening CT—Response

Patrick Maisonneuve, Vincenzo Bagnardi, Massimo Bellomi, and Giulia Veronesi

Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women

Jon J. Ladd, Tina Busald, Melissa M. Johnson, Qing Zhang, Sharon J. Pitteri, Hong Wang, Dean E. Brenner, Paul D. Lampe, Raju Kucherlapati, Ziding Feng, Ross L. Prentice, and Samir M. Hanash

A New Biomarker that Predicts Colonic Neoplasia Outcome in Patients with Hyperplastic Colonic Polyps

Catherine Do, Claudine Bertrand, Julien Palasse, Marie-Bernadette Delisle, Arthur Shulkes, Elizabeth Cohen-Jonathan-Moyal, Audrey Ferrand, and Catherine Seva

A Hexane Fraction of American Ginseng Suppresses Mouse Colitis and Associated Colon Cancer: Anti-inflamatory and Proapoptotic Mechanisms

Deepak Poudyal, Phuong Mai Le, Tia Davis, Anne B. Holseth, Alena Chumanevich, Alexander A. Chumanevich, Michael J. Wargovich, Mitzi Nagarkatti, Prakash S. Nagarkatti, Anthony Windust, and Lorne J. Hofseth
ABOUT THE COVER

The cover features a micropictogram (80X magnification) of H & E staining of a paraffin-embedded liver section of a mouse that received metformin to reduce or prevent hepatocellular carcinoma. Metformin (given as 250 mg/kg of body weight in chow) inhibited hepatocellular carcinoma induced by the liver-specific carcinogen diethylnitrosamine (DEN) in C57BL/6j mice. Mice injected with DEN at 2 weeks of age were put on metformin or control chow after weaning. At 24 or 36 weeks post-DEN treatment, liver-tumor multiplicity and size were reduced significantly in metformin-fed versus control-fed mice. Representative H & E sections indicate that the pathology of tumors in metformin-fed (featured on the cover) and control-fed mice (not shown) were similar, despite the decrease in tumor formation. In the cover image, the prominent oval shape at the bottom is a blood vessel in the portal tract (with additional vascular spaces below it). Just above and left of this vessel, a hepatocellular tumor appears as a circular cluster of larger cells with enlarged nuclei and somewhat more basophilic cytoplasm. See articles by Bhalla et al. (beginning on page 544) and by Pollak and Gonzalez-Angulo (beginning on page 500) for more information.